The team will develop a platform using phage display libraries to identify antibody variants specific to targeted tissues, enhancing the development of biologics for immune-oncology, autoimmunity, and other diseases through in vivo screening and next-generation sequencing.
Dr. Lauren Williamson is a translational immunologist developing next-generation antibody therapeutics for infectious diseases, cancer, and autoimmunity. At Vanderbilt, she leads efforts in antibody discovery and engineering, with a focus on monoclonal and bispecific formats, expression optimization, and phage display technologies. Her research has contributed to candidate therapeutics targeting Zika, Ebola, influenza, and other high-impact pathogens.
She is also the founder of TissueAb, a novel in vivo screening platform for identifying tissue-targeting antibodies with broad potential in precision medicine. Supported by Vanderbilt’s Innovation Catalyst Fund, the platform exemplifies Dr. Williamson’s focus on translating immunological advances into real-world therapeutic solutions.